Aptinyx Stock Forecast, Price & News

Aptinyx (NASDAQ:APTX) Frequently Asked Questions

Is Aptinyx a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aptinyx stock.
View analyst ratings for Aptinyx or view top-rated stocks.

How has Aptinyx's stock price been impacted by COVID-19 (Coronavirus)?

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APTX shares have decreased by 11.5% and is now trading at $2.15.
View which stocks have been most impacted by COVID-19.

Are investors shorting Aptinyx?

Aptinyx saw a decrease in short interest in November. As of November 15th, there was short interest totaling 468,400 shares, a decrease of 20.0% from the October 31st total of 585,600 shares. Based on an average trading volume of 162,400 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1.5% of the shares of the stock are sold short.
View Aptinyx's Short Interest.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Aptinyx.

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31). During the same quarter in the previous year, the company posted ($0.24) EPS.
View Aptinyx's earnings history.

What price target have analysts set for APTX?

4 analysts have issued 12 month price targets for Aptinyx's shares. Their forecasts range from $8.00 to $8.00. On average, they expect Aptinyx's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 272.1% from the stock's current price.
View analysts' price targets for Aptinyx or view top-rated stocks among Wall Street analysts.

Who are Aptinyx's key executives?

Aptinyx's management team includes the following people:

• Norbert G. Riedel, Chief Executive Officer & Director
• Andrew Kidd, President & Chief Operating Officer
• Ashish Khanna, Chief Financial & Business Officer
• Harald Murck, Vice President-Clinical & Medical Affairs
• Kathryn King, Senior Vice President-Clinical & CMC Operations

Who are some of Aptinyx's key competitors?

Some companies that are related to Aptinyx include Theravance Biopharma (TBPH), Phathom Pharmaceuticals (PHAT), Applied Molecular Transport (AMTI), Inventiva (IVA), Fulcrum Therapeutics (FULC), SIGA Technologies (SIGA), Arbutus Biopharma (ABUS), DiaMedica Therapeutics (DMCAF), ORIC Pharmaceuticals (ORIC), OrganiGram (OGI), ESSA Pharma (EPIX), Karyopharm Therapeutics (KPTI), Basilea Pharmaceutica (BPMUF), ANI Pharmaceuticals (ANIP) and Immuneering (IMRX).
View all of APTX's competitors.

What other stocks do shareholders of Aptinyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), (KDMN), Matinas BioPharma (MTNB), Cidara Therapeutics (CDTX), ADMA Biologics (ADMA), DURECT (DRRX) and Catalyst Pharmaceuticals (CPRX).

When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.54%), Renaissance Technologies LLC (0.70%), Two Sigma Advisers LP (0.37%), Morgan Stanley (0.32%), Dimensional Fund Advisors LP (0.17%) and Raymond James & Associates (0.17%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Bain Capital Life Sciences Inv, Norbert G Riedel, Rachel E Sherman and Robert J Hombach.
View institutional ownership trends for Aptinyx.

Which institutional investors are selling Aptinyx stock?

APTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Advisers LP, Millennium Management LLC, Morgan Stanley, Dimensional Fund Advisors LP, Two Sigma Investments LP, Squarepoint Ops LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Aptinyx or view top insider-selling stocks.

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $2.15.

How much money does Aptinyx make?

Aptinyx has a market capitalization of $145.59 million and generates $1.56 million in revenue each year. The company earns $-50.05 million in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Aptinyx have?

Aptinyx employs 34 workers across the globe.

What is Aptinyx's official website?

The official website for Aptinyx is www.aptinyx.com.

Where are Aptinyx's headquarters?

Aptinyx is headquartered at 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201.

How can I contact Aptinyx?

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at (847) 871-0377 or via email at [email protected].